BridgeMD
Obesity and Semaglutide in Type 1 Diabetes Therapy (OBES1TY): A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial
EU CTIS ID: 2025-522326-13-00
What this study is testing
The main objective is to assess the effect of semaglutide on body weight in patients with T1D and obesity.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Type 1 Diabetes for 3 years or more
- Obesity defined by BMI equal to or higher than 30
- Obesity defined by BMI equal to or higher than 27 and obesity-related diagnosis registered in the electronic patient journal such as: hypertension, hypercholesterolemia, dyslipidemia, micro albuminuria, ischemic heart disease, stroke, atherosclerosis or athrosis)
- Age equal to or higher than 18 years
You likely can't join if
- Other forms of diabetes
- Alcohol or other drug abuse
- Receipt of an investigational drug within 30 days prior to visit 0
- Simultaneous participation in any other clincal intervention trial
- Other concomitant disease or treatment that according to the investigators assessment makes the patient unsuited for study participation
- GLP1-RA use in the last 6 months
See the full eligibility criteria
- Type 1 Diabetes for 3 years or more
- Obesity defined by BMI equal to or higher than 30
- Obesity defined by BMI equal to or higher than 27 and obesity-related diagnosis registered in the electronic patient journal such as: hypertension, hypercholesterolemia, dyslipidemia, micro albuminuria, ischemic heart disease, stroke, atherosclerosis or athrosis)
- Age equal to or higher than 18 years
- Other forms of diabetes
- Alcohol or other drug abuse
- Receipt of an investigational drug within 30 days prior to visit 0
- Simultaneous participation in any other clincal intervention trial
- Other concomitant disease or treatment that according to the investigators assessment makes the patient unsuited for study participation
- GLP1-RA use in the last 6 months
- Known intolerance of Semaglutide
- Pregnant or nursing women
- Fertile women not using chemical or hormonal contraceptives
- Liver disease with elevated plasma levels of alanine aminotransferase (>5 times upper limit of reference interval) or aspartate aminotransferase (>5 times upper limit).
- Acute or chronic pancreatitis
- Known cancer disease, unless in complete remission for > 5 years or unless basocellular carcinomas
- History of thyroid adenoma or carcinoma
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.